A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeutic in Subjects With Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination With Sunitinib.
Phase of Trial: Phase II
Latest Information Update: 23 Apr 2015
At a glance
- Drugs Rocapuldencel-T (Primary) ; Sunitinib
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Sponsors Argos Therapeutics Inc
- 31 Aug 2018 Biomarkers information updated
- 21 Apr 2015 Results published in the Journal for ImmunoTherapy of Cancer, according to a Argos Therapeutics Inc media release.
- 18 Sep 2014 Results published in Argos Therapeutics media release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History